Stockreport

Cardiff Oncology announces positive colorectal data and $40m stock oversubscription [Yahoo! Finance]

Cardiff Oncology, Inc.  (CRDF) 
PDF evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The Phase II trial (NCT0 [Read more]